Suppr超能文献

发现具有泛 TAIRE 家族特异性的共价 CDK14 抑制剂。

Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity.

机构信息

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.

出版信息

Cell Chem Biol. 2019 Jun 20;26(6):804-817.e12. doi: 10.1016/j.chembiol.2019.02.015. Epub 2019 Mar 28.

Abstract

Cyclin-dependent kinase 14 (CDK14) and other TAIRE family kinases (CDKs 15-18) are proteins that lack functional annotation but are frequent off-targets of clinical kinase inhibitors. In this study we develop and characterize FMF-04-159-2, a tool compound that specifically targets CDK14 covalently and possesses a TAIRE kinase-biased selectivity profile. This tool compound and its reversible analog were used to characterize the cellular consequences of covalent CDK14 inhibition, including an unbiased investigation using phospho-proteomics. To reduce confounding off-target activity, washout conditions were used to deconvolute CDK14-specific effects. This investigation suggested that CDK14 plays a supporting role in cell-cycle regulation, particularly mitotic progression, and identified putative CDK14 substrates. Together, these results represent an important step forward in understanding the cellular consequences of inhibiting CDK14 kinase activity.

摘要

周期蛋白依赖性激酶 14(CDK14)和其他 TAIRE 家族激酶(CDKs15-18)是缺乏功能注释但却是临床激酶抑制剂频繁的非靶点的蛋白质。在这项研究中,我们开发并表征了 FMF-04-159-2,这是一种专门针对 CDK14 共价结合的工具化合物,具有 TAIRE 激酶偏向的选择性特征。该工具化合物及其可逆类似物被用于表征共价 CDK14 抑制的细胞后果,包括使用磷酸化蛋白质组学进行无偏见的研究。为了减少混杂的非靶点活性,使用洗脱条件来分解 CDK14 特异性作用。这项研究表明,CDK14 在细胞周期调控中发挥支持作用,特别是在有丝分裂进展中,并确定了潜在的 CDK14 底物。总之,这些结果代表着在理解抑制 CDK14 激酶活性的细胞后果方面向前迈出了重要的一步。

相似文献

1
Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity.发现具有泛 TAIRE 家族特异性的共价 CDK14 抑制剂。
Cell Chem Biol. 2019 Jun 20;26(6):804-817.e12. doi: 10.1016/j.chembiol.2019.02.015. Epub 2019 Mar 28.

引用本文的文献

10
Quantifying CDK inhibitor selectivity in live cells.定量活细胞中的 CDK 抑制剂选择性。
Nat Commun. 2020 Jun 2;11(1):2743. doi: 10.1038/s41467-020-16559-0.

本文引用的文献

2
Kinase inhibitors: the road ahead.激酶抑制剂:前路漫漫。
Nat Rev Drug Discov. 2018 May;17(5):353-377. doi: 10.1038/nrd.2018.21. Epub 2018 Mar 16.
3
Glimmers in illuminating the druggable genome.揭示可用药基因组的曙光。
Nat Rev Drug Discov. 2018 May;17(5):301-302. doi: 10.1038/nrd.2017.252. Epub 2018 Jan 19.
4
The target landscape of clinical kinase drugs.临床激酶药物的目标格局。
Science. 2017 Dec 1;358(6367). doi: 10.1126/science.aan4368.
5
The Cysteinome of Protein Kinases as a Target in Drug Development.蛋白激酶半胱氨酸组作为药物开发的靶点。
Angew Chem Int Ed Engl. 2018 Apr 9;57(16):4372-4385. doi: 10.1002/anie.201707875. Epub 2018 Feb 2.
8
Defining a Cancer Dependency Map.定义癌症依赖图谱。
Cell. 2017 Jul 27;170(3):564-576.e16. doi: 10.1016/j.cell.2017.06.010.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验